Crescent, you are smart enough to know that the XBI is made up of a lot of biotechs in different stages of their life cycle. Pre-revenue (and, even more so, pre-approval) companies within that index are much more volatile than the index as a whole. Since you own it as well, it shouldn't surprise you that SAVA is down an identical 61% from its 52 week high.
News 
Market Data 
Discover 
